FDA Approves Rockwell's Triferic For Iron Replacement In Hemodialysis Patients

(RTTNews) - Rockwell Medical Inc. (RMTI) announced the U.S. FDA has approved its drug Triferic for commercial sale as an iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease. Triferic is an iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron losses that occur during their dialysis treatment.

Robert Chioini, CEO of Rockwell, said: "Triferic is the first drug approved to replace ongoing iron losses and to maintain hemoglobin levels in hemodialysis patients. Triferic's unique ability to be delivered via dialysate and to deliver iron without increasing iron stores strengthens its potential to become the market-leading iron therapy treatment for hemodialysis patients."